LLY
Eli Lilly and Company
LLY has the edge over PLX overall, supported by lower modeled downside and stronger modeled upside.
PLX
Protalix BioTherapeutics, Inc.
PLX offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
PLX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
PLX's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
PLX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 11x | $2.96 | — |
| Cheap | 12x | $3.21 | +8.4% |
| Forward | 25x | $2.96 | — |
| Fair | 26x | $6.68 | +126% |
| Expensive | 43x | $11.27 | +281% |
Historical ranges are pointers, not guarantees.
PLX has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over PLX on the outlook, with more favorable valuation expectations.
PLX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect PLX to return to profit, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over PLX on earnings, with more consistent year-over-year improvement.
PLX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.12 | -54% |
| Q3 2026 | $0.26 | +225% |
| Q2 2026 | $0.24 | +200% |
| Q1 2026 | $0.19 | +280% |
| Q4 2025 | -$0.08 | -300% |
| Q3 2025 | $0.08 | +$0.17 |
| Q2 2025 | $0.08 | +$0.24 |
| Q1 2025 | $0.05 | -38% |
| Q4 2024 | $0.04 | -56% |
PLX's earnings per share have jumped to their highest in six years: $0.26 over the past year, up from $0.08 the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over PLX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over PLX on profitability, with a higher operating margin.
PLX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $21.9M | +23% |
| Q2 2026 | $19.9M | +27% |
| Q1 2026 | $33.8M | +234% |
| Q4 2025 | $9.1M | -50% |
| Q3 2025 | $17.9M | -0.6% |
| Q2 2025 | $15.7M | +16% |
| Q1 2025 | $10.1M | +170% |
| Q4 2024 | $18.2M | +74% |
PLX's revenue is recovering but still below its 2023 peak: $22M last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +6.5 points |
| Q2 2026 | 23% | +16 points |
| Q1 2026 | 63% | +104 points |
| Q4 2025 | -51% | -91 points |
| Q3 2025 | 12% | -10 points |
| Q2 2025 | 7.5% | +26 points |
| Q1 2025 | -41% | +89 points |
| Q4 2024 | 40% | +93 points |
PLX's operating margin was 18% last quarter, up 6.5 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over PLX on cash flow, with more consistent year-over-year improvement.
PLX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.2M | +$7.4M |
| Q2 2026 | -$11M | -$5.3M |
| Q1 2026 | $21.3M | +$26.6M |
| Q4 2025 | $1.6M | -54% |
| Q3 2025 | -$4.2M | -205% |
| Q2 2025 | -$5.7M | -$1.9M |
| Q1 2025 | -$5.4M | -249% |
| Q4 2024 | $3.6M | +6.6% |
PLX's free cash flow has turned positive again: $15M over the past year, against −$12M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over PLX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
PLX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +1M shares |
| 1 year | +3.4% | +2.8M shares |
| 3 years | -0.2% | -196K shares |
| 5 years | +84% | +38.1M shares |
| Available history | +463% | +68.7M shares |
PLX has 84M diluted shares, up 3.4% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
PLX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.8x | Net Cash |
| Q2 2026 | -1.1x | Net Cash |
| Q1 2026 | -1.9x | Net Cash |
| Q3 2025 | -1.8x | Net Cash |
| Q2 2025 | -1.9x | Net Cash |
| Q1 2025 | -3.3x | Net Cash |
| Q4 2024 | -3.8x | Net Cash |
| Q1 2024 | -2.9x | Net Cash |
PLX has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
PLX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.4 | Neutral |
| Stochastic | 65.9 | Neutral |
PLX's weekly RSI is 65 (neutral) and its Stochastic is 66 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
PLX PE vs Healthcare Sector
| Metric | PLX | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 26x | 56% below |
| PE % | 13 | 29 | 16 pts below |
PLX has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
PLX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.68 | 10% above |
| 20 week MA | $2.55 | 16% above |
| 50 week MA | $2.35 | 26% above |
| 100 week MA | $2.18 | 36% above |
| 200 week MA | $1.87 | 58% above |
PLX is in an uptrend: it's above all five of its weekly moving averages, and 58% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
PLX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.79 | $3.44 | +23% |
| 2021 | $3.44 | $0.95 | -72% |
| 2022 | $0.95 | $1.18 | +24% |
| 2023 | $1.18 | $1.78 | +51% |
| 2024 | $1.78 | $1.83 | +2.8% |
| 2025 | $1.83 | $1.81 | -1.1% |
| 2026 YTD | $1.81 | $2.96 | +64% |
PLX has the edge over LLY on returns for 2026, with the stronger performance.